Sirolimus Prophylaxis for aGVHD in TME SCID
| Status: | Withdrawn |
|---|---|
| Conditions: | Infectious Disease, HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any - 1 |
| Updated: | 4/21/2016 |
| Start Date: | July 2014 |
| End Date: | November 2015 |
Sirolimus in Prevention of aGVHD in Maternally Engrafted (TME) Severe Combined Immunodeficiency (SCID) Infants Receiving Unconditioned Hematopoietic Stem Cell Transplant (HSCT)
Study Design: SCID infants receiving an unconditioned haploidentical transplant will be
started on Sirolimus (0.05 mg/kg/day) day -5 for Acute Graft-Versus-Host Disease (aGVHD)
prophylaxis. Sirolimus levels will be monitored with goal sirolimus trough level of 5-8
ng/mL. Patients will be monitored for signs of aGVHD as defined by UCSF SOP CL 221.06
through day +100. Sirolimus will be tapered once T-regulatory cell to CD4 effector cell
ratio is > or = 9%.
Setting: Inpatient BMT Unit Benioff Children's Hospital at UCSF Medical Center
Study Subjects: 15 infants with diagnosis of maternally engrafted T cells SCID by CA Newborn
screen receiving unconditioned haploidentical HSCT
Main Outcome Measures: Incidence of aGVHD (dermatitis, hepatitis, enteritis) as defined by
SOP CL 221.06 by Day +100.
Hypothesis 1. Patients placed on sirolimus prophylaxis will have lower incidence of aGVHD
compared to historical controls.
Hypothesis 2. Lower doses of sirolimus milligram per kilogram will be required to maintain
goal troughs of 5-8 ng/mL.
started on Sirolimus (0.05 mg/kg/day) day -5 for Acute Graft-Versus-Host Disease (aGVHD)
prophylaxis. Sirolimus levels will be monitored with goal sirolimus trough level of 5-8
ng/mL. Patients will be monitored for signs of aGVHD as defined by UCSF SOP CL 221.06
through day +100. Sirolimus will be tapered once T-regulatory cell to CD4 effector cell
ratio is > or = 9%.
Setting: Inpatient BMT Unit Benioff Children's Hospital at UCSF Medical Center
Study Subjects: 15 infants with diagnosis of maternally engrafted T cells SCID by CA Newborn
screen receiving unconditioned haploidentical HSCT
Main Outcome Measures: Incidence of aGVHD (dermatitis, hepatitis, enteritis) as defined by
SOP CL 221.06 by Day +100.
Hypothesis 1. Patients placed on sirolimus prophylaxis will have lower incidence of aGVHD
compared to historical controls.
Hypothesis 2. Lower doses of sirolimus milligram per kilogram will be required to maintain
goal troughs of 5-8 ng/mL.
Inclusion Criteria:
- Infants diagnosed with SCID on CA newborn screen
- Evidence of Maternal Engraftment
- Unconditioned haploidentical hematopoeitic stem cell transplant
Exclusion Criteria:
- Evidence of acute graft vs. host disease
We found this trial at
1
site
Click here to add this to my saved trials
